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Introduction

Across the United States, children diagnosed with acute lymphoblastic leukemia (ALL) following
Children’s Oncology Group (COG) protocols undergo standard 3 or 4-drug induction chemotherapy.
However, length of stay (LOS) and antibiotic practices during induction chemotherapy vary by
institution. Much less is known about hospital practices and outcomes during induction chemotherapy
from small institutions similar to ours. At our institution, there are on average 30 to 35 newly diagnosed
oncology patients every year. Previously, our hospital practice included keeping high risk patients
undergoing 4-drug induction chemotherapy longer in the hospital through absolute neutrophil count
(ANC) nadir prior to discharge home. According to Wedekind et al,1 long LOS hospitals had lower
odds of any readmission. Of note, such odds were higher in patients >10 years or girls, with the top
2 most common diagnoses at readmission being neutropenia and fever.1 Literature suggests that
infectious complications occur in 20-35% of patients undergoing induction chemotherapy. Slone et
al2 found 39% of patients had infectious complications during induction chemotherapy with a 25%
readmission rate. According to Sulis et al,3 reported bacterial infections during induction chemotherapy
accounted for 25% of patients. Other factors such as young age, white race, intensive chemotherapy,
and lack of neutrophil surge after dexamethasone treatment was associated with infection-related
complications.4 After several infectious complications in one year at our institution, the purpose of
this retrospective review was to evaluate the influence of our hospital practices in relation to
morbidity during induction chemotherapy within the last decade of care.

Methods

• Retrospective chart review
• Inclusion criteria: Patients 1 to 21 years of age
with newly diagnosed ALL or lymphoblastic
lymphoma (LLy) at our institution between
May 1, 2020 and May 31, 2020
• Exclusion criteria: infant ALL, acute myeloid
leukemia (AML), and Down’s Syndrome
• Eligible patients had to complete entirety of
induction chemotherapy at our institution
• Infectious complications during initial
hospitalization were defined as documented
bacterial infection during hospital stay prior
to discharge. This included positive
microbiological culture, sepsis, clinical
findings of abscess or cellulitis, and/or
radiological evidence of deep soft
tissue infection.
• Readmission infectious complication was
defined as documented bacterial infection
or fever on readmission.

Statistical Analysis

• Length of stay (LOS) categorized as the
following, taking into account for patients
with weekend admissions and time to
chemotherapy initiation:
Short LOS ≤11 days
Medium LOS 12-15 days
Long LOS ≥16 d
• Fever was defined as at least one oral
temperature of 38.3°C or two consecutive
temperatures
of 38°C in 1 hour.
• Readmission period included the first 30
days following the initial day of admission for
diagnosis and induction chemotherapy.

The primary outcome was to evaluate infectious complications and readmission rates during
induction chemotherapy. Two patient groups were compared in regard to LOS, type of induction,
age, sex, comorbidities, risk stratification, and central line type utilizing t-test, where appropriate.
Two-sided tests of significance were utilized and a P< 0.05 were specified as statistically
significant. A multivariate analysis has not been performed yet.
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Results

Of the 72 patients, 14 (19%) had infectious complications during the entirety of induction chemotherapy
(Table II). Only 9 (13%) patients were readmitted for infectious complications or fever. The most
common infectious complication during induction chemotherapy included bacteremia and neutropenic
fever (Table II). The most common organism found on readmission was methicillin-susceptible
Staphylococcus aureus (MSSA) bacteremia (56%). Patients undergoing 3-drug induction had
increased rates of infectious complications during induction chemotherapy as compared to those
undergoing 4-drug induction (Table III).

Table I: Demographic characteristics
of the 72 patients during induction
chemotherapy 		
Age
1-10 years
>10 years
Sex
Female
Male
Race
White
African American
Asian
Other
Unknown
Ethnicity
Hispanic
Non-Hispanic
Unknown
Comorbidities
Yes
No
Central line type
PICC
MediPort
ALL categorization
B-ALL
T-ALL
T-LLy
ALL risk stratification
High risk B-ALL
Standard risk B-ALL
Chemotherapy protocol
3-drug induction
4-drug induction

N (%)

53 (74%)
19 (26%)
30 (42%)
42 (58%)

P-value

<0.00001
0.0549

52 (72%)
4 (6%)
1 (1%)
10 (14%)
5 (7%)
13 (18%)
57 (79%)
2 (3%)
68 (94%)
4 (6%)

<0.00001

44 (61%)
28 (39%)

0.0083

22 (31%)
38 (53%)

0.0076

40 (56%)
32 (44%)

0.1499

Induction protocol
3-drug induction (N=40)
4-drug induction (N=32)
P-value
Readmission rate
3-drug induction (N=40)
4-drug induction (N=32)

Table II: Infectious complication
characteristics during induction
chemotherapy
Total Infectious Complications
Bacteremia
Methicillin-susceptible
Staphylococcus aureusa
Escherichia colib
Pseudomonas
Group B streptococcus
Streptococcus pneumoniae
Moraxella
Sepsis, blood culture negative
C. difficile infection
Neutropenic fever
Non-neutropenic fever
Osteomyelitis
Pyomyositis
Intussusception
Ecthyma

N (%)
14 (19%)
5 (36%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)
5 (36%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)
1 (7%)

On readmission, Methicillin-susceptible Staphylococcus aureus bacteremia
was the predominate organism found at 56%
b
Escherichia coli bacteremia was the second most common organism at 11%;
MRSA, Methicillin-resistant Staphylococcus aureus was not found. No deaths
were identified.
a

60 (83%)
9 (13%)
3 (4%)

Table IV: Length of stay and readmission rate for infectious complications
between those patients undergoing 3-drug verse 4-drug induction
chemotherapy protocols

Table III: Infectious complications during
induction chemotherapy between those
undergoing 3-drug verse 4-drug
induction chemotherapy protocols
Chemotherapy protocol
3-drug induction
4-drug induction

N (%)
9 (64%)
5 (36%)

PICC, peripherally inserted central catheter; B-ALL, B-cell acute lymphoblastic
leukemia; T-ALL, T-cell acute lymphoblastic leukemia; T-LLy, T-cell lymphoblastic
lymphoma.

There were significant differences in LOS. Twenty-two of the 40 patients (55%) who received 3-drug
induction had short LOS (≤11 d) as compared to 5 (16%) of the 32 patients with 4-drug induction
(P=0.0007). Contrary, 26 (81%) of these patients had long LOS (≥16 d) as compared to 10 (25%) of
patients who received 3-drug induction (P=<0.00001). Both of these findings were statistically
significant (Table IV). Most of the few patients undergoing 4-drug induction chemotherapy with short
LOS were readmitted with infectious complications (60%). This was also statistically significant.
Interestingly, most of the readmitted patients were <10 years of age (Table V).

P-value

Short LOSa
(%) (range)

Medium LOSb
(%) (range)

Long LOSc
(%) (range)

22 (55%) (6-11d)
5 (16%) (6-10d)

8 (20%) (12-14d)
1 (13%) (13d)
0.429

10 (25%) (15-30d)
26 (81%) (16-33d)

2 (25%)
0
0.569

2 (20%)
1 (4%)
0.121

0.0007
1 (5%)
3 (60%)
0.002

LOS, length of stay; aShort LOS defined as ≤11 days; bMedium LOS defined as 12-15 days; cLong LOS defined as ≥16 days.

<0.00001

Table V: Readmission rate for infectious complications evaluated by age
Readmission rate
Age <10 years
Age ≥10 years

N (%)

P-value

7 (78%)
2 (22%)

0.017

Conclusion

We found lower (19%) but comparable total rate of infectious complications during ALL
induction chemotherapy as reported in the literature.2,3 However, our rate of readmission (13%)
as well as rates of infectious complications or fever when readmitted, was much lower.
Furthermore, when stratified by NCI risk group or 3-drug vs. 4-drug induction, we did not see
a difference. Similarly, to Inaba et al,4 we found that young age (<10 years) was associated with
increased rate of infectious complications on readmission during induction (78%). Limits of the
study include the retrospective nature of the review as well as the lack of a robust statistical
analysis that accounted for a variety of factors including multivariate analysis. Our study
demonstrated that patients undergoing 4-drug induction chemotherapy who had a short LOS
(≤11 days) had increased rates of readmission and infectious complications. On the contrary,
patients undergoing 3-drug induction chemotherapy with short LOS had lower rates of
readmission for infectious complications. We believe the practice of keeping SR patients until at
least day 8 of induction and most of those receiving 4-drug induction past absolute neutrophil
count nadir or LOS ≥16 days, may account for our favorable findings. Now, with literature
supporting levofloxacin prophylaxis during induction chemotherapy for prevention of febrile
neutropenia and systemic infection5, earlier discharge for high-risk patients is a consideration.
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